Scarica l'app Stockscreener
219.84
6.88%
-16.23
Dopo l'orario di chiusura:
219.80
-0.04
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$236.07
Aprire:
$226.138
Volume 24 ore:
2.03M
Relative Volume:
2.16
Capitalizzazione di mercato:
$15.48B
Reddito:
$2.71B
Utile/perdita netta:
$247.10M
Rapporto P/E:
62.80
EPS:
3.5008
Flusso di cassa netto:
$349.90M
1 W Prestazione:
-7.24%
1M Prestazione:
-9.43%
6M Prestazione:
-35.68%
1 anno Prestazione:
-10.15%
Intervallo 1D:
$216.49
$230.43
Intervallo di 1 settimana:
$216.49
$241.90
Portata 52W:
$216.49
$354.88
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
219.84 | 15.48B | 2.71B | 247.10M | 349.90M | 3.5008 |
|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
How The Insulet (PODD) Narrative Is Shifting With Omnipod 5 And Rising Competition - Yahoo Finance
Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness - Yahoo Finance
Insulet Stock To $154? - Trefis
Why Insulet (PODD) Is Down 7.2% After Omnipod 5 Recall Over Insulin Under-Delivery Risk - finance.yahoo.com
Insulet Corporation stock hits 52-week low at 226.14 USD - Investing.com India
Insulet Corporation stock hits 52-week low at 226.14 USD By Investing.com - Investing.com South Africa
Insulet recalls specific Omnipod 5 insulin pump lots after injuries By Investing.com - Investing.com Australia
Securities Fraud Investigation Into Insulet Corporation (PODD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - Carroll County Mirror-Democrat
Insulet Corporation (PODD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - WFXG
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
FDA announces recall of insulin delivery pods - Cardiovascular Business
Securities Fraud Investigation Into Insulet Corporation (PODD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
Insulet to spend up to $40M on Omnipod 5 pod recall - The Business Journals
Insulet initiates Omnipod 5 recall following 18 AE reports - Yahoo Finance
Insulet falls as Omnipod 5 Pod medical device correction spotlights manufacturing issue - Quiver Quantitative
Insulin devices recalled over leak risk, reports of 'serious adverse events' - LiveNOW from FOX
Insulet reports 18 serious adverse events with recall of Omnipod 5 insulin pumps - MedTech Dive
Insulet (PODD) Faces Stock Dip After Voluntary Device Correction - GuruFocus
Insulet recalling certain defective Omnipod insulin delivery devices - MSN
Insulet Begins Voluntary Medical Device Correction for Certain Omnipod 5 Pods in the U.S. - Medical Product Outsourcing
Insulet Stock Hits 52-Week Low - Benzinga
Insulet recalling Omnipod insulin delivery units (PODD:NASDAQ) - Seeking Alpha
Insulet Corporation (PODD) Announces Voluntary Medical Device Co - GuruFocus
INSULET recalls specific Omnipod 5 pods due to insulin leak risk - StreetInsider
Insulet recalls some insulin devices in US over leakage risk - Reuters
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Insulet (PODD) Addresses Manufacturing Issue in Omnipod 5 Pods - GuruFocus
Insulet Issues Voluntary Omnipod 5 Device Correction - TipRanks
Insulet recalls specific Omnipod 5 insulin pump lots after injuries - Investing.com
Insulet (NASDAQ: PODD) faces Omnipod 5 pod correction with up to $40M cost - Stock Titan
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S. - Business Wire
Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System - Medical Product Outsourcing
Swiss National Bank Reduces Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Holdings Boosted by Capital Fund Management S.A. - MarketBeat
Insulet (PODD) AID System Shows Promise in Diabetes Management - GuruFocus
Insulet presents study results for fully closed-loop automated insulin delivery system - marketscreener.com
Insulet Reports Positive Results From Automated Insulin Pump Trial - marketscreener.com
Insulet reports positive results for closed-loop diabetes system - StreetInsider
Insulet Corporation Presents Promising Study Results For Fully Closed-Loop Automated Insulin Delivery System For Adults With Type 2 Diabetes - marketscreener.com
Insulet (PODD): Citigroup Adjusts Price Target Amid Buy Rating | - GuruFocus
Magnetar Financial LLC Has $7.12 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
Citigroup Adjusts Price Target on Insulet to $338 From $345, Maintains Buy Rating - marketscreener.com
Korea Investment CORP Sells 17,419 Shares of Insulet Corporation $PODD - MarketBeat
Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - BioSpace
Insulet Corporation $PODD Shares Sold by Capital Research Global Investors - MarketBeat
Vinva Investment Management Ltd Makes New Investment in Insulet Corporation $PODD - MarketBeat
Avoiding Lag: Real-Time Signals in (PODD) Movement - Stock Traders Daily
Published on: 2026-03-09 05:40:12 - baoquankhu1.vn
Rhenman & Partners Asset Management AB Grows Stock Position in Insulet Corporation $PODD - MarketBeat
Blair William & Co. IL Sells 20,182 Shares of Insulet Corporation $PODD - MarketBeat
Insulet stock: Is the Omnipod maker your next stealth growth play? - AD HOC NEWS
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):